{{Rsnum
|rsid=16905691
|Gene=PCDH15
|Chromosome=10
|position=55949899
|Orientation=plus
|GMAF=0.3691
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 3.5 | 23.0 | 73.5
| HCB | 72.3 | 25.5 | 2.2
| JPT | 83.2 | 15.0 | 1.8
| YRI | 10.2 | 31.3 | 58.5
| ASW | 3.5 | 36.8 | 59.6
| CHB | 72.3 | 25.5 | 2.2
| CHD | 78.0 | 18.3 | 3.7
| GIH | 19.8 | 47.5 | 32.7
| LWK | 3.6 | 31.8 | 64.5
| MEX | 12.3 | 35.1 | 52.6
| MKK | 5.8 | 31.4 | 62.8
| TSI | 3.9 | 21.6 | 74.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs16905691
|Name_s=
|Gene_s=PCDH15
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00002. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109444
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs16905691
|overall_frequency_n=38
|overall_frequency_d=128
|overall_frequency=0.296875
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=35
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}